Shots:
- Incyte has partnered with Enable Injections to develop and commercialize specific assets in Incyte’s portfolio, incl. INCA033989, a mutCALR selective mAb, with Enable’s enFuse On-Body Delivery System
- As per the deal, Incyte will obtain exclusive global rights to use enFuse tech with INCA033989 for essential thrombocythemia & myelofibrosis, with potential expansion to other assets & indications, in exchange for an undisclosed upfront, research, development & commercial milestone payments, & transfer pricing for enFuse clinical & commercial supply
- enFuse system enables SC delivery of large-volume biologics & small molecules, incl. at-home self-administration
Ref: Incyte | Image: Incyte & Enable Injections | Press Release
Related News:- GSK Secures Exclusive License to Syndivia’s ADC Candidate for Prostate Cancer
PharmaShots! Your go-to media platform for customized news ranging for multiple indications. For more information connect with us at connect@pharmashots.com
